[1]
Beca, J., Majeed, H., Chan, K.K., Hotte, S.J., Loblaw, A. and Hoch, J.S. 2019. Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer. Canadian Urological Association Journal. 13, 12 (Apr. 2019), 396-403. DOI:https://doi.org/10.5489/cuaj.5889.